VeraStem Security Rating

Verastem Oncology is a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Its pipeline is focused on small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth inhibition. Verastem Oncology develops VS-6766, an orally available small molecule RAF/MEK inhibitor that blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK; and defactinib, a targeted inhibitor of FAK that is a non-receptor tyrosine kinase encoded by the protein tyrosine kinase-2 (PTK-2) gene that is involved in cellular adhesion and, in cancer, metastatic capability.